Skip to main content

Table 3 Baseline characteristics, comorbidities and clinical features of patients in the uncommon NFGNB group vs. the common NFGNB group

From: Epidemiology of bacteremia caused by uncommon non-fermentative gram-negative bacteria

Variables

Uncommon NFGNB

Common NFGNB

Unadjusted OR

P-value

(N = 86)

(N = 135)

[95% CI]

 

Median age (interquartile range), years

55 (37–70)

54 (37–71)

0.996 [0.984-1.007]

0.44

Median length of stay prior to bacteremia onset (interquartile range), days

1.5 (0–12)

10 (2–20)

0.996 [0.986-1.005]

0.37

Male sex

30 (34.9%)

86 (63.7%)

0.31 [0.17-0.56]

<0.001

Services

    

  ▪ Medicine

49 (57.0%)

81 (60.0%)

0.54 [0.26-1.13]

0.13

   Surgery

17 (19.8%)

36 (26.7%)

0.43 [0.18-1.00]

 

   Others

20 (23.2%)

18 (13.3%)

Reference group

 

Underlying diseases

    

   Hematologic malignancies

11 (12.8%)

38 (28.2%)

0.37 [0.16-0.81]

0.007

   Cardiovascular diseases

44 (51.2%)

45 (33.3%)

2.10 [1.16-3.78]

0.008

   Chronic renal diseases

18 (20.9%)

17 (12.6%)

1.83 [0.83-4.06]

0.10

   Chronic liver diseases

7 (8.1%)

9 (6.7%)

1.24 [0.38-3.91]

0.68

   Chronic lung diseases

4 (4.7%)

9 (6.7%)

0.68 [0.15-2.55]

0.77*

   Solid tumor

21 (24.4%)

27 (20.0%)

1.29 [0.64-2.59]

0.44

   Diabetes

23 (26.7%)

26 (19.3%)

1.53 [0.76-3.05]

0.19

   HIV infection

1 (1.2%)

1 (0.7%)

1.58 [0.20-124.65]

0.99*

   Receiving immunosuppressive agents

6 (7.0%)

5 (3.7%)

1.95 [0.48-8.33]

0.28

   Neurological diseases

2 (2.3)

6 (4.4%)

0.51 [0.05-2.96]

0.49*

Recent antibiotic exposure within 30 d

    

   All antibiotics

44 (51.2%)

95 (70.4%)

0.44 [0.24-0.80]

0.004

   Beta-lactams

40 (46.5%)

88 (65.2%)

0.46 [0.26-0.84]

0.006

   Cephalosporins

22 (25.6%)

53 (39.3%)

0.53 [0.28-1.00]

0.04

   Carbapenems

13 (15.1%)

21 (15.6%)

0.97 [0.42-2.17]

0.93

   Beta-lactam/beta-lactamase inhibitors

10 (11.6%)

24 (17.8%)

0.61 [0.25-1.42]

0.22

   Fluoroquinolones

9 (10.5%)

12 (8.9%)

1.20 [0.42-3.26]

0.70

   Aminoglycosides

5 (5.8%)

25 (18.5%)

0.27 [0.08-0.77]

0.007

  Polymyxin E

3 (3.5%)

1 (0.7%)

4.84 [0.38-256.08]

0.30*

   Vancomycin

13 (15.1%)

12 (8.9%)

1.83 [0.72-4.62]

0.15

   Metronidazole

1 (1.2%)

15 (11.1%)

0.09 [0.002-0.64]

0.006*

   Cotrimoxazole

0

6 (4.4%)

….

0.84*

   Clindamycin

3 (3.5%)

9 (6.7%)

0.51 [0.09-2.11]

0.38*

Clinical characteristics

    

Hospital-acquired infection

55 (64.0%)

112 (83.0%)

0.36 [0.18-0.72]

<0.001

Sites of infection

    

  • Primary bacteremia

31 (36.1%)

18 (13.3%)

3.66 [1.79-7.56]

<0.001

  • Pneumonia

24 (27.9%)

52 (38.5%)

0.62 [0.33-1.15]

0.11

  • Urinary tract

5 (5.8%)

15 (11.1%)

0.49 [0.14-1.51]

0.18

  • Gastrointestinal tract

8 (9.3%)

17 (12.6%)

0.72 [0.25-1.85]

0.45

  • Catheter-related infection

12 (13.9%)

9 (6.7%)

2.27 [0.83-6.39]

0.07

  • Soft tissue and surgical site infection

0

7 (5.2%)

….

0.05*

  • Febrile neutropenia

4 (4.7%)

15 (11.1%)

0.39 [0.09-1.29]

0.14*

  • Others

1 (1.2%)

1 (0.7%)

1.58 [0.20-124.65]

0.99*

Infection-related mortality

15 (17.4%)

71 (52.6%)

0.19 [0.09-0.38]

<0.001

  1. Note: * Fisher's exact p-value.